Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
An open-label, phase III trial evaluating tebentafusp or the investigator’s choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine in previously untreated HLA-A*02:01–positive patients with metastatic uveal melanoma
Primary outcome measures:
Overall survival (OS)
The authors concluded that treatment with tebentafusp resulted in more prolonged overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma
Nathan et al. 2021 N Engl J Med 385:1196-1206
…